News for 'Sun Pharma'

Sensex jumps nearly 450 pts on buying in metal shares

Sensex jumps nearly 450 pts on buying in metal shares

Rediff.com12 Dec 2025

Among Sensex firms, Tata Steel, Eternal, UltraTech Cement, Larsen & Toubro, Maruti and Bharti Airtel were the major gainers. However, Hindustan Unilever, Sun Pharma, ITC and Asian Paints were among the laggards.

Paid Rs 1.35L Insurance Premium: 'Can I Get It Back?'

Paid Rs 1.35L Insurance Premium: 'Can I Get It Back?'

Rediff.com8 Jan 2026

Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.

Sensex climbs over 158 points on buying in tech and IT shares

Sensex climbs over 158 points on buying in tech and IT shares

Rediff.com4 Dec 2025

Tata Consultancy Services, Tech Mahindra, Infosys, HCL Tech, Bharti Airtel, Sun Pharma, Bharat Electronics and Trent were the major gainers among Sensex scrips. However, Maruti, Eternal, Kotak Mahindra Bank and Titan were among the laggards.

Stock markets end flat in highly volatile trade

Stock markets end flat in highly volatile trade

Rediff.com28 Nov 2025

Among Sensex firms, Power Grid, Eternal, Bharti Airtel, Axis Bank and Infosys were the biggest laggards. However, Mahindra & Mahindra, Sun Pharma, Kotak Mahindra Bank and State Bank of India were among the major gainers.

Cancer Therapies Break New Ground

Cancer Therapies Break New Ground

Rediff.com26 Dec 2025

'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'

Lower input costs may aid pharma firms' Q2 margins

Lower input costs may aid pharma firms' Q2 margins

Rediff.com21 Oct 2024

Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.

Where The Deadly Cough Syrup Was Made

Where The Deadly Cough Syrup Was Made

Rediff.com18 Oct 2025

Sandwiched between a Hero MotoCorp showroom and a shop that hires out cooking utensils is a small, dingy building that's been locked up. The non-descript two-room building is a manufacturing unit of Sresan Pharmaceuticals, the pharma company made its Coldriff cough syrup that has allegedly killed 25 children in Madhya Pradesh.

Sensex jumps over 513 points on buying in IT stocks

Sensex jumps over 513 points on buying in IT stocks

Rediff.com19 Nov 2025

From the Sensex pack, HCL Tech, Infosys, Tata Consultancy Services, Hindustan Unilever, Sun Pharma and Titan were among the biggest gainers. In contrast, Tata Motors Passenger Vehicles, Maruti, Adani Ports and Bajaj Finance were among the laggards.

Netra Mantena's Fab Bridal Looks

Netra Mantena's Fab Bridal Looks

Rediff.com25 Nov 2025

From beautifully decorated venues glowing under fairy lights to celebrity guests' dance performances, every function felt straight out of a Bollywood dream sequence. The biggest scene stealer, however, was Netra's wedding wardrobe.

Sensex drops over 331 points on last-minute selling

Sensex drops over 331 points on last-minute selling

Rediff.com24 Nov 2025

Among Sensex firms, Bharat Electronics, Mahindra & Mahindra, Tata Steel, UltraTech Cement, Bajaj Finserv and Tata Motors Passenger Vehicles were the major laggards. However, Tech Mahindra, Asian Paints, Infosys, Adani Ports, Sun Pharma and HDFC Bank were the gainers.

Kapil Sharma-Priyanka Provide The Laughs On OTT

Kapil Sharma-Priyanka Provide The Laughs On OTT

Rediff.com19 Dec 2025

It's raining sequels on OTT this week, but that's not all. Sukanya Verma lists everything you can watch.

Sensex, Nifty close marginally lower after hitting fresh lifetime highs

Sensex, Nifty close marginally lower after hitting fresh lifetime highs

Rediff.com1 Dec 2025

Among Sensex firms, Bajaj Finance, Sun Pharma, Trent, Mahindra & Mahindra, State Bank of India and Bajaj Finserv were the major laggards. However, Tata Motors Passenger Vehicles, Maruti, Bharat Electronics, Kotak Mahindra Bank, Adani Ports and HCL Tech were among the gainers.

Healthcare IPOs See A Surge In 2025

Healthcare IPOs See A Surge In 2025

Rediff.com8 Jan 2026

The surge has come alongside a decline in average issue sizes and more muted listing-day returns compared with last year.

Alerted Centre, MP govt about toxic cough syrup: TN minister

Alerted Centre, MP govt about toxic cough syrup: TN minister

Rediff.com10 Oct 2025

Tamil Nadu government alerted Madhya Pradesh and the Union Health Ministry about the presence of a toxic substance in Coldrif cough syrup, averting a major tragedy, according to state Health Minister Ma Subramanian.

Despite short-term blip, Sun Pharma remains favourite among investors

Despite short-term blip, Sun Pharma remains favourite among investors

Rediff.com28 Dec 2024

Around six weeks ago, Sun Pharmaceutical Industries, India's largest drugmaker, suffered a setback, which led to a selloff in the share. The US District Court of New Jersey granted Incyte's request for a preliminary injunction against Sun Pharma's launch of Leqselvi, a drug that treats alopecia.

Stock markets rally as RBI cuts rate; Sensex jumps 447 points

Stock markets rally as RBI cuts rate; Sensex jumps 447 points

Rediff.com5 Dec 2025

From the Sensex firms, State Bank of India, Bajaj Finserv, Bajaj Finance, Maruti, HCL Tech, Larsen & Toubro, Mahindra & Mahindra and Infosys were among the major winners. However, Hindustan Unilever, Eternal, Tata Motors Passenger Vehicles, and Sun Pharma were among the laggards.

'From March 2026, India Should Resume Long-Term Uptrend'

'From March 2026, India Should Resume Long-Term Uptrend'

Rediff.com29 Sep 2025

'Indian markets may underperform global peers for the next two quarters.' 'But beyond that, India should catch up and resume its long-term growth path.'

India terms EU envoys' article unusual before key Putin visit

India terms EU envoys' article unusual before key Putin visit

Rediff.com3 Dec 2025

India and Russia are poised to sign multiple agreements to bolster cooperation in various sectors, including trade and healthcare, during Russian President Vladimir Putin's visit to New Delhi. Discussions will also address the Ukraine conflict and efforts to increase Indian exports to Russia.

USFDA's new draft biosimilar rules to benefit Indian biotech cos

USFDA's new draft biosimilar rules to benefit Indian biotech cos

Rediff.com9 Nov 2025

The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.

Infant dies in MP after taking Ayurvedic cough syrup

Infant dies in MP after taking Ayurvedic cough syrup

Rediff.com31 Oct 2025

A five-month-old girl has died in Chhindwara district in Madhya Pradesh allegedly after consuming an Ayurvedic cough syrup and a medicinal powder, an official said on Friday.

Will India continue to remain an attractive FDI destination in 2026?

Will India continue to remain an attractive FDI destination in 2026?

Rediff.com27 Dec 2025

FDI inflows into India are expected to register robust growth in 2026, supported by strong macroeconomic fundamentals, big-ticket investment announcements, sustained efforts to improve the ease of doing business, and a new generation of investment-linked trade pacts.

'I Didn't Want To Do Bigg Boss, But...'

'I Didn't Want To Do Bigg Boss, But...'

Rediff.com10 Dec 2025

JioStar's SouthUnbound event served as the launchpad for several new original projects on the streaming platform.

Not neutral, India is on the side of peace, Modi tells Putin

Not neutral, India is on the side of peace, Modi tells Putin

Rediff.com5 Dec 2025

Prime Minister Narendra Modi strongly supported efforts to end the war in Ukraine and conveyed to Russian President Vladimir Putin that India will stand shoulder-to-shoulder in all peace efforts to find an amicable solution to the conflict.

Stock markets rally on US Fed rate cut hopes, fresh foreign fund inflows

Stock markets rally on US Fed rate cut hopes, fresh foreign fund inflows

Rediff.com29 Oct 2025

From the Sensex firms, Adani Ports, NTPC, Power Grid, HCL Tech, Tata Steel, Sun Pharma, Trent and Asian Paints were among the major gainers. However, Bharat Electronics, Eternal, Mahindra & Mahindra and Maruti were among the laggards.

Cough Medicine Deaths: Rajasthan Suspends Drug Controller

Cough Medicine Deaths: Rajasthan Suspends Drug Controller

Rediff.com4 Oct 2025

The Rajasthan government has suspended the state drug controller and halted the distribution of medicines manufactured by Kaysons Pharma following reports of children's deaths allegedly linked to contaminated cough syrup.

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Rediff.com11 Jun 2024

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.

No deaths due to codeine syrup, accused linked to SP: Yogi

No deaths due to codeine syrup, accused linked to SP: Yogi

Rediff.com22 Dec 2025

Uttar Pradesh Chief Minister Yogi Adityanath on Monday strongly rebutted allegations by Leader of Opposition Mata Prasad Pandey over 'deaths' allegedly due to the consumption of fake medicines and codeine syrup, asserting in the Assembly that no such case has come to the notice of the state government so far.

Mankind Pharma to lead in Indian women's health market after BSV deal

Mankind Pharma to lead in Indian women's health market after BSV deal

Rediff.com29 Jul 2024

New Delhi-based pharmaceutical major Mankind Pharma is poised to take pole position in women's health portfolio in the India Pharma Market (IPM) after completing the Rs 13,630 crore deal to acquire Bharat Serums and Vaccines (BSV), senior company officials said. The deal potentially opens doors for Mankind Pharma to the overseas markets, which currently draws 92 per cent of its revenues from India. The combined entity will draw around 13 per cent revenues from the international market, with the remaining coming from the domestic market.

Sensex jumps 1,022.50 points; Nifty inches near record high

Sensex jumps 1,022.50 points; Nifty inches near record high

Rediff.com26 Nov 2025

Among Sensex firms, Bajaj Finserv, Bajaj Finance, Tata Steel, Reliance Industries, Sun Pharma, Tata Motors Passenger Vehicles, Axis Bank and Infosys were among the major gainers. Bharti Airtel and Asian Paints emerged as the laggards from the pack.

Sensex jumps 595 points on strong global cues

Sensex jumps 595 points on strong global cues

Rediff.com12 Nov 2025

From the Sensex pack, Asian Paints, Tech Mahindra, Tata Consultancy Services, Bajaj Finserv, Adani Ports, HCL Technologies, Bharti Airtel, Infosys, Trent, Reliance Industries, UltraTech Cement, Sun Pharmaceuticals, Eternal, Titan and Bajaj Finance were the gainers. On the other hand, Tata Steel, Tata Motors Passenger Vehicles, Tata Motors Commercial Vehicles, Bharat Electronics, Kotak Mahindra Bank and PowerGrid were the laggards.

17 persons killed, 33 hurt in Andhra pharma unit fire

17 persons killed, 33 hurt in Andhra pharma unit fire

Rediff.com22 Aug 2024

Harrowing scenes unfolded at the SEZ where the fire ripped through the pharma company. Injured workers with torn clothes and bleeding injuries were seen being shifted to hospitals in ambulances.

Russia strikes Indian pharma warehouse in Ukraine

Russia strikes Indian pharma warehouse in Ukraine

Rediff.com13 Apr 2025

A Russian missile struck a warehouse belonging to an Indian pharmaceutical company, Kusum, in Ukraine, according to the Ukrainian embassy in India. The embassy alleged that Russia, despite claiming a "special friendship" with India, deliberately targeted Indian businesses in Ukraine. The strike reportedly destroyed medicines intended for children and the elderly. This incident follows a similar attack on a major pharmaceuticals warehouse in Kyiv, which was destroyed by Russian drones, as reported by the UK's ambassador to Ukraine. Kusum Healthcare, the company whose warehouse was hit, has a presence in 29 countries, including Ukraine. This attack comes amidst ongoing tensions in the region as Russia continues its offensive against Ukraine, despite US efforts to push for a ceasefire. Ukrainian Foreign Minister Andrii Sybiha accused Russia of being the sole obstacle to peace and claimed that Moscow rejected a US-brokered proposal for a ceasefire.

Budget 2024: Wishlist of the pharma industry

Budget 2024: Wishlist of the pharma industry

Rediff.com8 Jul 2024

There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.

JioHotStar Is Investing 4K Cr In South!

JioHotStar Is Investing 4K Cr In South!

Rediff.com10 Dec 2025

The platform has seen a growth of 70% in watch time for South content, which is more than the national average.The South has outperformed the rest of India in subscription depth, retention and connected TV adoption.

Rupee Fall: Who Stands To Gain?

Rupee Fall: Who Stands To Gain?

Rediff.com25 Nov 2025

So far this year, the rupee has fallen by 4.2 per cent, the worst among its Asian peers.

Selling in blue-chips RIL, HDFC Bank drag Sensex down by 153 points

Selling in blue-chips RIL, HDFC Bank drag Sensex down by 153 points

Rediff.com8 Oct 2025

Among Sensex firms, Tata Motors, Mahindra & Mahindra, Bharat Electronics, UltraTech Cement, Trent, Sun Pharma, Power Grid and Reliance Industries were the major laggards. However, Titan, Infosys, Tata Consultancy Services, HCL Tech and Tech Mahindra were among the biggest gainers.

Cipla Q2 profit up 3.7% at Rs 1,353 cr

Cipla Q2 profit up 3.7% at Rs 1,353 cr

Rediff.com30 Oct 2025

Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company, which had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, said its managing director & global CEO, Umang Vohra, has decided not to seek re-appointment upon completion of his current term on March 31, 2026, Cipla Ltd said in a regulatory filing.

Putin to land in Delhi soon, Modi to host private dinner

Putin to land in Delhi soon, Modi to host private dinner

Rediff.com4 Dec 2025

Prime Minister Narendra Modi will host Russian President Vladimir Putin for a private dinner and summit, focusing on defence, trade, and geopolitical issues, including the Ukraine conflict and the impact of US sanctions.

The Lady Who Designed The Billionaire Wedding

The Lady Who Designed The Billionaire Wedding

Rediff.com9 Dec 2025

When Chennai-based Wedding Designer Ambika Gupta first received a brief for a destination wedding in Udaipur, she had no idea it would turn into one of the most high-profile celebrations of the season.

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Rediff.com23 Dec 2024

India's healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According to data, key contributors to the record fundraising included Sai Life Sciences (Rs 3,043 crore), IKS Health (Rs 2,498 crore), and Sagility India (Rs 2,107 crore).